

## Special Issue

# Biotechnologies Applied in Vaccine Research

### Message from the Guest Editor

Traditional vaccines can be classified as inactivated vaccines, live attenuated vaccines, and subunit vaccines given orally, via intramuscular (IM) injection, and via subcutaneous (SC) injection. Recently, recombinant protein vaccines, DNA vaccines, mRNA vaccines, and multiple/alternative administration route vaccines have been developed for human use to make vaccines more secure and effective. These vaccine platforms have been developed using various biotechnologies, such as adenovirus vectors, nanoparticles, mRNA, recombination DNA, and other vaccine delivery systems. In this Special Issue, we are inviting contributions related to advances in biotechnologies applied in vaccine research. It will explore the biotechnologies applied in the development of vaccine research and platforms. We welcome original research articles and reviews. Research areas may include vaccines, biotechnology, vaccine vectors, DNA, mRNA, subunits, novel adjuvants, and delivery systems. We look forward to receiving your contributions.

---

### Guest Editor

Dr. Yuan-Chuan Chen

Department of Nursing and Department of Medical Technology, Jenteh Junior College of Medicine, Nursing and Management, Miaoli County 35664, Taiwan

---

### Deadline for manuscript submissions

closed (31 August 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/197687](https://mdpi.com/si/197687)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).